Skip to content

Contact +44 (0) 20 7060 7474 email us

Cancer

Leukemia - A Therapeutic & Competitive Insight

 

Publication Date October 2006
Publisher Bioseeker
Product Type Report
Pages 141
ISBN Number not applicable
Product Code BSK00134

Price

£1,745.00
approximately: $2,642 | €1,948

pdf

Buy Now

print

Buy Now

Order above formats by FAX

Order by Fax

Summary

Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry.

This has now clearly changed with the launch of Novartis' Gleevec (imatinib mesylate) for chronic myeloid leukemia (CML), which is presenting the industry with proof that development within the leukemia market produces lucrative returns. Gleevec saw sales rise 32 percent to $2.2 billion during 2005. Consequently, the historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected.

Research and analysis highlights

In the report"Leukemia - A Therapeutic & Competitive Insight" BioSeeker does not only describe and analyze the latest years of progress in four different market segments; CLL, CML ALL and AML, but also provide a insight and framework to understand the complex field of leukemia therapeutics. In this report, we provide one of the most comprehensive coverage of the R&D trends to set the future leukemia marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified 85 drug candidates in phase II or III stage of development and more than 50 companies are involved in the development of these drugs. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in several of the leukemic sub-markets and current treatments will be changed for the benefit of more innovative therapies.

Scope of this report

  • Thorough examination of status and impact of several novel drugs in development
  • Discussion of the challenges in current and future treatment strategies
  • Anticancer pipeline of most companies in the field
  • Key reasons to read this report
  • Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in leukemia R&D, and the results of clinical trials to date
  • Gain insight into the current challenges and commercial opportunities associated with leukemia therapy
  • More than 130 high quality references

Some of the drugs included in this analysis

AG-858, Alemtuzumab, AP23573, Atra, Avastin, BAY 43-9006, CEP-701, Ceplene, Clofarabine, Cloretazine, Decitabine, FK228, Flavopiridol, Gemtuzumab, Genasense, Gvax, Imatinib, OSI-461, PKC412, PTK787, Rituximab, SU5416, Troxacitabine, Valspodar, VELCADE, Xcytrin, Zarnestra etc.

Some of the companies included in this analysis

Amgen, Antigenics, Bayer, Bioenvision, Biogen Idec, BTG, Cell Genesys, Cephalon, Cyclacel Group (Cyclacel), Exelixis, Genta, GlaxoSmithKline, Johnson & Johnson, Millennium, Novartis, Pharmacyclics, PDL BioPharma, Schering-Plough, SuperGen, Vion Pharmaceuticals, Wyeth etc.

Contents

  • 1. Executive Summary
  • 2. Cancer Highlights
  • 3. Methodology
  • 4. Table of Contents
    • 4.1 List of Boxes
    • 4.2 List of Tables
  • 5. Introduction
    • 5.1 Disease Definitions
      • 5.1.1 The Lymphoid Malignancies
      • 5.1.2 The Myeloid Malignancies
    • 5.2 Etiology & Pathophysiology
      • 5.2.1 The Lymphoid Malignancies
      • 5.2.2 The Myeloid Malignancies
    • 5.3 Epidemiology
    • 5.4 Prognosis
      • 5.4.1 The Lymphoid Malignancies
      • 5.4.2 The Myeloid Malignancies
  • 6. Current Treatment Strategies
    • 6.1 The Lymphoid Malignancies
    • 6.2 The Myeloid Malignancies
  • 7. Progress in Current Treatment Strategies
    • 7.1 The Lymphoid Malignancies
    • 7.2 The Myeloid Malignancies
  • 8. Key Therapeutic Strategies for Future Therapies
    • 8.1 Therapeutic type, Targets & Mechanisms
  • 9. Competitive Landscape in Drug Development: The Late Stage Pipeline
    • 9.1 The Lymphoid Malignancies
    • 9.2 The Myeloid Malignancies
  • 10. Current Drug Development: The Early Stage Pipeline
    • 10.1 The Myeloid Malignancies
    • 10.2 The Lymphoid Malignancies
  • 11. Disclaimer
    • 11.1 Liability
    • 11.2 Completeness
  • 12. Appendix: Drugs Approved for the Treatment of Leukemia: A Historical Perspective
  • 13. Drug Index
  • 14. Company Index
  • List of Boxes
    • Box 1: Major treatment regimes
    • Box 2: CLL staging system
    • Box 3: Updated REAL/WHO Classification for B-Cell Neoplasms
    • Box 4: Quick Facts - Clofarabine
    • Box 5: Quick Facts - Alemtuzumab
    • Box 6: Quick Facts - Gemtuzumab
    • Box 7: Quick Facts - Imatinib
    • Box 8: Quick Facts - Rituximab
    • Box 9: Quick Facts - Genasense
    • Box 10: Quick Facts - Flavopiridol
    • Box 11: Quick Facts - Atra
    • Box 12: Quick Facts - Gvax
    • Box 13: Quick Facts - Zarnestra
    • Box 14: Quick Facts - BAY 43-9006
    • Box 15: Quick Facts - Ceplene
    • Box 16: Quick Facts - Valspodar
    • Box 17: Quick Facts - CEP-701
    • Box 18: Quick Facts - PKC412
    • Box 19: Quick Facts - SU5416
    • Box 20: Quick Facts - PTK787
    • Box 21: Quick Facts - Cloretazine
    • Box 22: Company statement on progress
    • Box 23: Quick Facts - Troxacitabine
    • Box 24: Quick Facts - FK228
    • Box 25: Quick Facts - Decitabine
    • Box 26: Quick Facts - VELCADE
    • Box 27: Velcade sales 2005
    • Box 28: Quick Facts - AG-858
    • Box 29: Quick Facts - Avastin
    • Box 30: Quick Facts - OSI-461
    • Box 31: Quick Facts - Xcytrin
    • Box 32: Quick Facts - AP23573
  • List of Tables
    • Table 1: ALL Classification
    • Table 2: Latest Approved Drugs for the Treatment of Leukemia
    • Table 3: Kinase Inhibitors in Development for the Treatment of Leukemia
    • Table 4: Near Term Progress Rituximab
    • Table 5: Near Term Progress Oblimersen
    • Table 6: Near Term Progress Alvocidib
    • Table 7: Near Term Progress ATRA
    • Table 8: Near Term Progress GVAX
    • Table 9: Near Tearm Progress HuM195
    • Table 10: Near Term Progress Zarnestra
    • Table 11: Near Term Progress Sorafenib
    • Table 12: Near Term Progress Valspodar
    • Table 13: Summary of Current Late Stage Pipeline
    • Table 14: Near Term Progress CEP-701
    • Table 15: Near Term Progress PKC412
    • Table 16: Near Term Progress SU5416
    • Table 17: Near Term Progress PTK787
    • Table 18: Near Term Progress VNP40101M
    • Table 19: Near Term Progress Troxacitabine
    • Table 20: Near Term Progress Decitabine
    • Table 21 Near Term Progress Bortezomib
    • Table 22 Near Term Progress AG-858
    • Table 23: Near Term Progress bevacizumab
    • Table 24: Near Term Progress OSI-461
    • Table 25: Near Term Progress Xcytrin
    • Table 26: Near Term Progress AP23573
    • Table 27: Summary of Current Early Stage Pipeline.